Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015, Article ID 131508, 7 pages
http://dx.doi.org/10.1155/2015/131508
Clinical Study

Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson’s Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study

1Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
2Hospital Santa Maria de Lleida, 25007 Lleida, Spain
3Hospital de Mataró, 08302 Barcelona, Spain
4Hospital del Mar, 08003 Barcelona, Spain
5Hospital de Granollers, 08401 Barcelona, Spain
6Hospital Son Espases, 07120 Barcelona, Spain
7Corporació Sanitària Parc Taulí, 08208 Barcelona, Spain
8Hospital de Martorell, 08760 Martorell, Spain
9Hospital General de Catalunya, 08915 Barcelona, Spain
10Hospital de Figueres, 17600 Girona, Spain
11Hospital Germans Trias i Pujol, 07014 Barcelona, Spain

Received 17 November 2014; Revised 3 February 2015; Accepted 5 February 2015

Academic Editor: Antonio Pisani

Copyright © 2015 Javier Pagonabarraga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Sleep disturbances occur frequently in patients with Parkinson’s disease (PD). The aim of this study was to investigate the effects of rotigotine on sleep fluctuations in a sample of PD patients with self-reported complaints of nocturnal awakenings. This prospective, open-label, observational, and multicenter study enrolled consecutive outpatients with PD and administered rotigotine (mean dose 8.9 mg/day) for 3 months. The primary endpoint was the change from baseline in sleep fragmentation, assessed using the sleep maintenance subscale score of the Parkinson’s Disease Sleep Scale (PDSS). The newly designed Parkinson’s Disease Sleep Fragmentation Questionnaire (PD-SFQ) was used to measure other sleep parameters. A total of 62 patients were enrolled (mean age 70.2 years; 66% male). At 3 months, rotigotine significantly improved sleep fragmentation from baseline on the PDSS-2 sleep maintenance subscale (from to ; ). Rotigotine also significantly improved nocturnal motor symptoms , restless legs-like symptoms , and nocturia . Rotigotine significantly improved self-reported complaints of sleep fragmentation in PD patients and could be a useful treatment to improve this specific sleep problem in PD. However, these results are based on a small and clinically heterogeneous sample so they must be taken cautiously.